Clinical trials: Mask
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Acute Infectious Conjunctivitis (Disorder)
The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.
- Trial name
- SCH1TAIC (NCT05356793)
- Testing
- SCH-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sacsh
Obstructive Sleep Apnea
The Evaluation of a Full Face Mask Seal for the Treatment of Obstructive Sleep Apnea
The investigation is a prospective, randomized, single blinded, crossover study. The investigation is designed to evaluate the performance, comfort and ease of use of the F\&P Trial Full Face Mask Seal amongst Obstructive Sleep…
- Trial name
- NCT03230877
- Testing
- Toffee full face mask with 'Improved Seal', Toffee full face mask with 'Normal Seal'
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Fisher and Paykel Healthcare
Unilateral Cataract Extraction, Congenital Cataract
A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
The purpose of this study is to evaluate the effect of OMS302 compared to phenylephrine when administered in irrigation solution during cataract extraction on intraoperative pupil diameter, acute postoperative pain, and safety in…
- Trial name
- ILR7 (NCT02132312)
- Testing
- OMS302, Phenylephrine HCl
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Omeros Corporation
Parkinson's Disease
Masked Faces in Parkinson Disease: Mechanism and Treatment
The purpose of this study is to examine the effectiveness of high intensity respiratory muscle strength training in treating blunted facial expression in people with Parkinson disease.
- Trial name
- NCT00350402
- Testing
- Respiratory muscle strength training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Florida
Inflammation, Pain
Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects…
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02329743
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- A.T. Resolve SARL
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RIDE (NCT00473382)
- Testing
- Ranibizumab
- Volunteers
- 382 people
- Sponsor
- Genentech, Inc.
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Inflammation
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
- Trial name
- NCT00429923
- Testing
- Difluprednate
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Sirion Therapeutics, Inc.
Dry Eye Syndromes, Dry Eye
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- ARISE-3 (NCT03937882)
- Testing
- RGN-259
- Where
- 20 sites in United States
- Volunteers
- 700 people
- Sponsor
- ReGenTree, LLC
Dry Eye Disease
Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT03452397
- Testing
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Oyster Point Pharma, Inc.
Obstructive Sleep Apnea
The Effectiveness of SensAwake™ for Continue Positive Airway Pressure Treatment of Obstructive Sleep Apnea Patients
This study will investigate Obstructive Sleep Apnea (OSA) and an automatically Adjusting Positive Airway Pressure (APAP) device with new technology called SensAwake™.
- Trial name
- NCT03294629
- Testing
- SensAwake™ modification
- Volunteers
- 35 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Allergic Conjunctivitis
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory…
- Trial name
- NCT01730872
- Testing
- Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ORA, Inc.
Allergic Conjunctivitis
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
- Trial name
- NCT04622345
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanda Pharmaceuticals
Cataract
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd.
- Trial name
- NCT03499873
- Testing
- Nepafenac 0.3% Oph Susp, Nepafenac 0.3% Oph Susp (reference)
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Actavis Inc.
Dry Eye
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
- Trial name
- NCT04747977
- Testing
- OTX-DED
- Where
- 15 sites in United States
- Volunteers
- 172 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
- Trial name
- NCT03248037
- Testing
- Netarsudil
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Cornea Research Foundation of America